{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:14699"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:14699","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Investigating the Effect of Perhexiline and FPER-1 in pulmonary Arterial Hypertension","abstract":"Pulmonay arterial hypertension (PAH) is a vascular remodelling disease whereby proliferation of pulmonary artery smooth muscle cells (PASMCs) is increased. The pathophysiology of the disease is not fully understood, but there is a growing body of evidence in the literature that supports the notion that PAH PASMCs exhibit a similar metabolic phenotype to that of cancer cells. Previous studies have shown that PAH PASMCs reprogram their energy metabolism to utilise glycolysis over oxidative phosphorylation for ATP production due to a reduction in pyruvate dehydrogenase (PDH) activity. In the present study, we hypothesised that by increasing PDH activity, perhexiline and the novel fluorinated perhexiline (FPER-1), both carnitine palmitoyltransferase 1 (CPT1) inhibitors, would restore PDH flux and hence increase oxidative phosphorylation, and attenuate PASMCs proliferation. Utilising cultured PASMCs from healthy and PAH patient donors, we showed that perhexiline and FPER-1 effectively attenuates the increased rate of proliferation of PASMCs from PAH donors, whilst maintaining cell viability. We futher propose a novel mechanism of action of perhexiline/FPER-1 in PAH PASMCs whereby both perhexiline and FPER-1 reduces PAH PASMC proliferation by suppressing the activation of the AKT pathway (reduced phosphorylation of AKTser473) and activating PDH (dephosphorylation of PDH-E1α ser293). Our findings demonstrate that both perhexiline and FPER-1 show promise as a novel therapeutic agent for reversing the increased PASMC proliferation apparent in PAH, but additional studies regarding the safety of FPER-1 as a therapy are required.","abstract_html":"Pulmonay arterial hypertension (PAH) is a vascular remodelling disease whereby proliferation of pulmonary artery smooth muscle cells (PASMCs) is increased. The pathophysiology of the disease is not fully understood, but there is a growing body of evidence in the literature that supports the notion that PAH PASMCs exhibit a similar metabolic phenotype to that of cancer cells. Previous studies have shown that PAH PASMCs reprogram their energy metabolism to utilise glycolysis over oxidative phosphorylation for ATP production due to a reduction in pyruvate dehydrogenase (PDH) activity. In the present study, we hypothesised that by increasing PDH activity, perhexiline and the novel fluorinated perhexiline (FPER-1), both carnitine palmitoyltransferase 1 (CPT1) inhibitors, would restore PDH flux and hence increase oxidative phosphorylation, and attenuate PASMCs proliferation. Utilising cultured PASMCs from healthy and PAH patient donors, we showed that perhexiline and FPER-1 effectively attenuates the increased rate of proliferation of PASMCs from PAH donors, whilst maintaining cell viability. We futher propose a novel mechanism of action of perhexiline/FPER-1 in PAH PASMCs whereby both perhexiline and FPER-1 reduces PAH PASMC proliferation by suppressing the activation of the AKT pathway (reduced phosphorylation of AKTser473) and activating PDH (dephosphorylation of PDH-E1α ser293). Our findings demonstrate that both perhexiline and FPER-1 show promise as a novel therapeutic agent for reversing the increased PASMC proliferation apparent in PAH, but additional studies regarding the safety of FPER-1 as a therapy are required.","abstract_has_math":false,"creators":["Keeler, Ross"],"institution":"University of Birmingham","degree_name":"m_sc","degree_level":"m_sc","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-07","date_published":"2024-07","updated_at":"2026-11-21T09:53:45Z","subjects":["Q Science (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000158740464"],"render_values":[{"text":"0000-0001-5874-0464","href":"https://orcid.org/0000-0001-5874-0464","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"https://etheses.bham.ac.uk/id/eprint/14699/1/Keeler2024MScByResearch.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A14699","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["british_heart_foundation"]},{"key":"dc:creator","label":"Author","values":["Keeler, Ross"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000158740464"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-07-19"]},{"key":"dc:date.issued","label":"Date","values":["2024-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cardiovascular Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://etheses.bham.ac.uk/id/eprint/14699/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_sc"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Q Science (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://etheses.bham.ac.uk/id/eprint/14699/1/Keeler2024MScByResearch.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Pulmonay arterial hypertension (PAH) is a vascular remodelling disease whereby proliferation of pulmonary artery smooth muscle cells (PASMCs) is increased. The pathophysiology of the disease is not fully understood, but there is a growing body of evidence in the literature that supports the notion that PAH PASMCs exhibit a similar metabolic phenotype to that of cancer cells. Previous studies have shown that PAH PASMCs reprogram their energy metabolism to utilise glycolysis over oxidative phosphorylation for ATP production due to a reduction in pyruvate dehydrogenase (PDH) activity. In the present study, we hypothesised that by increasing PDH activity, perhexiline and the novel fluorinated perhexiline (FPER-1), both carnitine palmitoyltransferase 1 (CPT1) inhibitors, would restore PDH flux and hence increase oxidative phosphorylation, and attenuate PASMCs proliferation. Utilising cultured PASMCs from healthy and PAH patient donors, we showed that perhexiline and FPER-1 effectively attenuates the increased rate of proliferation of PASMCs from PAH donors, whilst maintaining cell viability. We futher propose a novel mechanism of action of perhexiline/FPER-1 in PAH PASMCs whereby both perhexiline and FPER-1 reduces PAH PASMC proliferation by suppressing the activation of the AKT pathway (reduced phosphorylation of AKTser473) and activating PDH (dephosphorylation of PDH-E1α ser293). Our findings demonstrate that both perhexiline and FPER-1 show promise as a novel therapeutic agent for reversing the increased PASMC proliferation apparent in PAH, but additional studies regarding the safety of FPER-1 as a therapy are required."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Investigating the Effect of Perhexiline and FPER-1 in pulmonary Arterial Hypertension"]}]}],"canonical_facts":{"dc:contributor.sponsor":["british_heart_foundation"],"dc:creator":["Keeler, Ross"],"dc:date":["2024-07-19"],"dc:date.issued":["2024-07"],"dc:description.abstract":["Pulmonay arterial hypertension (PAH) is a vascular remodelling disease whereby proliferation of pulmonary artery smooth muscle cells (PASMCs) is increased. The pathophysiology of the disease is not fully understood, but there is a growing body of evidence in the literature that supports the notion that PAH PASMCs exhibit a similar metabolic phenotype to that of cancer cells. Previous studies have shown that PAH PASMCs reprogram their energy metabolism to utilise glycolysis over oxidative phosphorylation for ATP production due to a reduction in pyruvate dehydrogenase (PDH) activity. In the present study, we hypothesised that by increasing PDH activity, perhexiline and the novel fluorinated perhexiline (FPER-1), both carnitine palmitoyltransferase 1 (CPT1) inhibitors, would restore PDH flux and hence increase oxidative phosphorylation, and attenuate PASMCs proliferation. Utilising cultured PASMCs from healthy and PAH patient donors, we showed that perhexiline and FPER-1 effectively attenuates the increased rate of proliferation of PASMCs from PAH donors, whilst maintaining cell viability. We futher propose a novel mechanism of action of perhexiline/FPER-1 in PAH PASMCs whereby both perhexiline and FPER-1 reduces PAH PASMC proliferation by suppressing the activation of the AKT pathway (reduced phosphorylation of AKTser473) and activating PDH (dephosphorylation of PDH-E1α ser293). Our findings demonstrate that both perhexiline and FPER-1 show promise as a novel therapeutic agent for reversing the increased PASMC proliferation apparent in PAH, but additional studies regarding the safety of FPER-1 as a therapy are required."],"dc:format":["text"],"dc:identifier.uri":["https://etheses.bham.ac.uk/id/eprint/14699/1/Keeler2024MScByResearch.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cardiovascular Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["https://etheses.bham.ac.uk/id/eprint/14699/"],"dc:subject":["Q Science (General)"],"dcterms:accessrights":["public"],"dc:title":["Investigating the Effect of Perhexiline and FPER-1 in pulmonary Arterial Hypertension"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_sc"],"dc:type.qualificationname":["m_sc"],"person:identifier.orcid":["0000000158740464"]},"updated_at":"2026-11-21T09:53:45Z"}